FibroBiologics, Change In Working Capital from 2010 to 2024
| FBLG Stock | 2.15 0.01 0.46% |
Change In Working Capital | First Reported 2010-12-31 | Previous Quarter 493 K | Current Value 356.4 K | Quarterly Volatility 95.6 K |
Check FibroBiologics, Common financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among FibroBiologics, Common's main balance sheet or income statement drivers, such as Depreciation And Amortization of 453.3 K, Selling General Administrative of 2.9 M or Other Operating Expenses of 9.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 792. FibroBiologics, financial statements analysis is a perfect complement when working with FibroBiologics, Common Valuation or Volatility modules.
FibroBiologics, | Change In Working Capital |
Latest FibroBiologics, Common's Change In Working Capital Growth Pattern
Below is the plot of the Change In Working Capital of FibroBiologics, Common Stock over the last few years. It is the difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities. FibroBiologics, Common's Change In Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in FibroBiologics, Common's overall financial position and show how it may be relating to other accounts over time.
| Change In Working Capital | 10 Years Trend |
|
Change In Working Capital |
| Timeline |
FibroBiologics, Change In Working Capital Regression Statistics
| Arithmetic Mean | 214,693 | |
| Geometric Mean | 201,319 | |
| Coefficient Of Variation | 44.52 | |
| Mean Deviation | 68,309 | |
| Median | 172,000 | |
| Standard Deviation | 95,592 | |
| Sample Variance | 9.1B | |
| Range | 321K | |
| R-Value | 0.65 | |
| Mean Square Error | 5.7B | |
| R-Squared | 0.42 | |
| Significance | 0.01 | |
| Slope | 13,899 | |
| Total Sum of Squares | 127.9B |
FibroBiologics, Change In Working Capital History
About FibroBiologics, Common Financial Statements
FibroBiologics, Common stakeholders use historical fundamental indicators, such as FibroBiologics, Common's Change In Working Capital, to determine how well the company is positioned to perform in the future. Although FibroBiologics, Common investors may analyze each financial statement separately, they are all interrelated. For example, changes in FibroBiologics, Common's assets and liabilities are reflected in the revenues and expenses on FibroBiologics, Common's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in FibroBiologics, Common Stock. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Change In Working Capital | 493 K | 356.4 K |
Currently Active Assets on Macroaxis
When determining whether FibroBiologics, Common is a strong investment it is important to analyze FibroBiologics, Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact FibroBiologics, Common's future performance. For an informed investment choice regarding FibroBiologics, Stock, refer to the following important reports:Check out the analysis of FibroBiologics, Common Correlation against competitors. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics, Common. If investors know FibroBiologics, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.55) | Return On Assets (0.66) | Return On Equity (2.68) |
The market value of FibroBiologics, Common is measured differently than its book value, which is the value of FibroBiologics, that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics, Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics, Common's market value can be influenced by many factors that don't directly affect FibroBiologics, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.